Peak Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PKBO research report →
Price Chart
About the company
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges.
- CEO
- Hoyoung Huh
- IPO
- 2021
- Employees
- 6
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on PKBO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $520.31K
- P/E
- -3.13
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- -901.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -11.16%
- ROIC
- -10.28%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-1,673.558
- Net Income
- $-1,676.22-33.1%
- EPS
- $-0.02-44944.9%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.02
- 52W Low
- $0.02
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.78
- RSI (14)
- 43
- Avg Volume
- 0
No earnings-call transcripts are available for PKBO yet.
- Free Float
- 0.0%
- Shares Outstanding
- 23.12M
- Float Shares
- 0
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 24 | SBI INVESTMENT KOREA CO., LTD. | other | 83,800 |
| Nov 14, 24 | SBI INVESTMENT KOREA CO., LTD. | sell | 3,621,489 |
| Nov 14, 24 | Patel Sandip I | other | 763,316 |
| Nov 14, 24 | Patel Sandip I | sell | 400,000 |
| Nov 14, 24 | Patel Sandip I | sell | 47,364 |
| Nov 14, 24 | Patel Sandip I | other | 0 |
| Nov 14, 24 | Neal James R | other | 37,850 |
| Nov 14, 24 | Neal James R | other | 0 |
| Nov 14, 24 | Neal James R | sell | 37,850 |
| Nov 14, 24 | Neal James R | sell | 33,340 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PKBO coverage
Recent articles, reports, and earnings notes.
No research on PKBO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PKBO report →SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
accesswire.com · Oct 11
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
globenewswire.com · May 1
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari
prnewswire.com · Mar 5
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
globenewswire.com · Mar 5
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
globenewswire.com · Jan 4
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing
globenewswire.com · Sep 19
Peak Bio, Inc. Announces Up-listing to OTCQB Market
globenewswire.com · Aug 31
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
globenewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.